Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
303 Results for "
chronic obstructive
" in MedChemExpress (MCE) Product Catalog:
Products (303)
303 Results for "chronic obstructive" in MCE Product Catalog:
Cat. No.: HY-167939
CAS No.: 788821-30-7
Target:
Research Areas:
(R)-Bambuterol is a β2-receptor agonist with anti-asthmatic and colitis-improving activity. (R)-Bambuterol is indicated for the treatment of asthma and chronic obstructive pulmonary disease and has the advantage of a once-daily dosing and a favorable side effect profile. (R)-Bambuterol significantly reduced disease severity in a mouse model of colitis, more effectively than (RS)-Bambuterol or (S)-Bambuterol. (R)-Bambuterol can significantly reduce the levels of inflammatory cytokines and reduce the infiltration of macrophages in mice with colitis. (R)-Bambuterol also increases β2-adrenoceptor levels and reduces the expression of IL-6, IL-17 and other related proteins in colon tissue in a dose-dependent manner .
Cat. No.: HY-184087
CAS No.: 205807-59-6
Synonyms: TNF484
Target:
Research Areas:
PKF 242-484 (TNF484) is an orally active dual inhibitor of TACE/MMPs, with Ki values of 3.6, 0.1, 0.9, 1, and 4.5 nM against hMMP-1, hMMP-2, hMMP-3, hMMP-9, and hMMP-13, respectively. PKF 242-484 inhibits the enzymatic activities of MMPs and ADAM17, reduces the release of TNF-α, suppresses the proliferation, migration and invasion of cancer cells, and regulates inflammatory cell infiltration and cytokine production. PKF 242-484 can be used in studies related to airway inflammatory diseases such as asthma and chronic obstructive pulmonary disease, intestinal ischemia-reperfusion injury, epilepsy-induced neuronal damage, and hepatocellular carcinoma .
Cat. No.: HY-D3153
CAS No.: 2693397-68-9
Cat. No.: HY-L134
193 compounds
Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.
Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.
Cat. No.: HY-207120
CAS No.: 512837-95-5
Target:
Research Areas:
TSLP-IN-1 is a potent thymic stromal lymphopoietin (TSLP) inhibitor. TSLP-IN-1 disrupts TSLP-TSLPR protein-protein interaction, and downregulates IL-4 and IL-13. TSLP-IN-1 can be used for the research of inflammation diseases, such as skin disease, asthma, and allergies .
Cat. No.: HY-B0551AR
CAS No.: 7081-53-0
Target:
Research Areas:
Doxapram hydrochloride hydrate (Standard) is the analytical standard of Doxapram hydrochloride hydrate (HY-B0551A). This product is intended for research and analytical applications. Doxapram hydrochloride hydrate is a respiratory stimulant. Doxapram hydrochloride hydrate increases breathing rate and depth by acting on the brain's respiratory centers and peripheral chemoreceptors. Doxapram hydrochloride hydrate inhibits TASK-1, TASK-3, TASK-1/TASK-3 heterodimeric channel function with EC50s of 410 nM, 37 μM, 9 μM, respectively. Doxapram hydrochloride hydrate inhibits the Ca²⁺-activated potassium current (IC50 ≈ 13 μM) and Ca²⁺-independent potassium current (IC50 ≈ 20 μM) in type I cells of the carotid body. Doxapram hydrochloride hydrate significantly prolongs the effective refractory period of the atrium and has an anti-arrhythmic effect. Doxapram hydrochloride hydrate can be used for the study of respiratory depression such as post-anesthesia respiratory depression, chronic obstructive pulmonary disease and apnea of prematurity.
Cat. No.: HY-B0551S
Target:
Research Areas:
SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury . SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases .
Cat. No.: HY-148527
CAS No.: 1347232-69-2
Synonyms: AZD8999
Research Areas:
LAS190792 is a bifunctional muscarinic acetylcholine receptor (mAChR) antagonist and β2-adrenergic receptor agonist. LAS190792 has a pIC50 of 8.8 against human M3 muscarinic receptor and a pIC50 of 9.1 against human β2-adrenergic receptor. LAS190792 exhibits vasodilatory and anti-inflammatory activities, and induces sustained bronchodilation in dogs. LAS190792 inhibits the release of IL-8, MMP9, IL-1β and GM-CSF from lipopolysaccharide-stimulated neutrophils. LAS190792 can be used in research related to respiratory system diseases .
Cat. No.: HY-185172
CAS No.: 2750575-21-2
Research Areas:
PDE4-IN precursor (Compound 10) is an orally active prodrug of phosphodiesterase 4 (PDE4) inhibitor. PDE4-IN precursor undergoes enzymatic hydrolysis in the colon to release the active PDE4 inhibitor, which exerts local anti-inflammatory effects on the colonic mucosa. PDE4-IN precursor is applicable to research related to ulcerative colitis, Crohn's disease, and other relevant conditions .
Cat. No.: HY-184076
CAS No.: 2978107-47-8
Research Areas:
Ibrilparant is a LPA1 receptor antagonist with an IC50 of 0.00753 μM. Ibrilparant exhibits LPA1 calcium flux antagonistic activity, with an IC50 of 3.02 nM. Ibrilparant can be used in research related to various diseases such as cancer and inflammatory diseases .
Cat. No.: HY-143683S
CAS No.: 1782458-84-7
Synonyms: 1,3-Dimethylxanthine-13C2,d6; Theo-24-13C2,d6
Cat. No.: HY-L223
861 compounds
Antitussive and antiasthmatic method is a type of treatment strategy in traditional Chinese medicine, mainly used to alleviate symptoms such as coughing and asthma. These symptoms may be caused by various factors, such as: Bronchial asthma, chronic obstructive pulmonary disease, asthmatic bronchitis, cough-induced asthma, and others. Based on existing research in traditional Chinese medicine, many types of Chinese medicinal herbs showed antitussive and antiasthmatic effects. For example: Ardisiae Japonicae Herba, Ginkgo Semen, Amygdalus Communis Vas, Farfarae Flos, Viticis Cannabifoliae Fructus, Eriobotryae Folium etc. Therefore, the active ingredients derived from these traditional Chinese medicine have high medicinal value and have the potential to be developed into drugs for related diseases.
MCE can provide 861 active ingredients that can be obtained from traditional Chinese medicine with antitussive and antiasthmatic functions, which can be applied to drug development and research on disease mechanisms.
Synonyms: 7-Desacetoxy-6,7-dehydrogedunin
Target:
PERK Prokineticin Receptor P2X Receptor Caspase NOD-like Receptor (NLR) Pyroptosis Tyrosinase
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
7DG (7-Desacetoxy-6,7-dehydrogedunin) is a PKR inhibitor, P2X7 purinergic receptor inhibitor, and skin-lightening agent. 7DG binds outside the ATP-catalytic domain of PKR, blocks the kinase activity-independent protein-protein interactions of PKR, inhibits the phosphorylation and activity of PKR, disrupts ASC assembly and caspase-1 activation, and suppresses the activation of the NLRP1 inflammasome. 7DG inhibits pyroptosis, suppresses the ATP-P2X7 signaling pathway, and abolishes ATP-induced increases in the expression levels of MITF, tyrosinase, PMEL/gp100, and melanin content. 7DG exerts skin-lightening effects in cultured skin in vitro. 7DG can be used in research related to chronic obstructive pulmonary disease, gout, type 2 diabetes, Alzheimer's disease, and hyperpigmentary skin disorders .
Cat. No.: HY-179503
Target:
Phosphodiesterase (PDE) TRP Channel NOD-like Receptor (NLR) NF-κB TNF Receptor Interleukin Related
Research Areas:
PDE/TRPA1/CHIT1-IN-1 is a phosphodiesterases (PDEs), TRPA1, and hCHIT1 (KD of 37.7 μM) inhibitor. PDE/TRPA1/CHIT1-IN-1 is a broad-spectrum PDE inhibitor, potently targeting key isoforms including PDE4B, PDE7A, PDE3A, and PDE8A with IC50s of 15.54, 15.15, 8.39 and 16.46 μM. PDE/TRPA1/CHIT1-IN-1 suppresses NLRP3 inflammasome activation and inhibits NF-κB phosphorylation, downregulating the expression of pro-inflammatory genes (TNF-α and IL-6) in vivo. PDE/TRPA1/CHIT1-IN-1 can be used for chronic obstructive pulmonary disease (COPD) and related inflammatory lung disorders research .
Cat. No.: HY-L087
3,741 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.
MCE Anti-Obesity Compound Library owns a unique collection of 3,741 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.
Target:
Research Areas:
p-Ethoxychrysoidin is a benzotriazole-based NLRP3 inhibitor. p-Ethoxychrysoidin can be used in research on inflammatory diseases and neurodegenerative diseases .
Cat. No.: HY-W714853
CAS No.: 65732-07-2
Target:
Research Areas:
(+)-Theta-cypermethrin is a stereoisomer of Cypermethrin (HY-B0829) that possesses blood-brain barrier penetration ability and binds to AKT1, SRC, STAT3 and EGFR with high affinity. (+)-Theta-cypermethrin reduces the amplitude of delayed rectifier potassium channel currents, shifts the steady-state activation curve to negative potentials, and shifts the steady-state inactivation curve to negative potentials at higher concentrations. (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons. (+)-Theta-cypermethrin causes chronic respiratory system damage and exhibits neurotoxicity .
Cat. No.: HY-152656
CAS No.: 15763-11-8
Target:
Research Areas:
2-Hydrazinyl-adenosine is a synthetic intermediate. Derivatives of 2-Hydrazinyl-adenosine act as A2A adenosine receptor agonists. 2-Hydrazinyl-adenosine is used in the research of neurodegenerative diseases .
Cat. No.: HY-176512
CAS No.: 3100308-37-7
FO-32 is an ionizable lipid and mRNA delivery carrier with state-of-the-art aerosolized mRNA delivery capability. FO-32 delivers mRNA to mouse muscle, nasal mucosa, lung, as well as ferret lung epithelium (including conducting airways). FO-32 can be used in studies related to the generation of lipid nanoparticles (LNPs) and the optimization of drug delivery .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
